To test whether the protective effect of cysteine in ES2 and OVCAR3 cells is concentration-dependent, cells (5 10 5 cells/well) were seeded in 6-well plates and cultured in control condition and exposed to 0.1 mM, 0.2 mM, 0.4 mM, 0.8 mM and 1.0 mM L-cysteine and/or hypoxia induced with 0.1 mM cobalt chloride
This is clinically relevant because obesity itself is associated with numerous health conditions that might influence treatment tolerance, including metabolic syndrome, cardiovascular disease, sleep apnea, and hepatic steatosis
Furthermore, key features include: 99% purity, confirmed by reverse-phase HPLC with controlled impurity profiles 10 mg vial format Lyophilized powder suitable for controlled laboratory reconstitution and measured research use Selective multi-receptor activity Binds melanocortin receptors (MC1R, MC3R, MC4R, MC5R) for comprehensive receptor pharmacology investigations Engineered stability Nle and D-Phe substitutions at positions 4 and 7 enhance enzymatic resistance compared to native -MSH cAMP-dependent signaling Investigated for activation of second-messenger cascades and downstream transcriptional responses Stable freeze-dried formulation Lyophilized for long-term stability at 18 C with minimal degradation For laboratory research use only These properties support its use as MT 1 for research across receptor pharmacology, cell signaling, pigmentation biology, and mechanistic studies of melanocortin-mediated pathways. How is MT-1 synthesized
Large cardiovascular outcome trials have demonstrated that several agents in this class reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes, with benefits extending beyond just those with established cardiovascular disease in some trials
doi: 10.1016/j.msec.2020.111660
